vadimezan has been researched along with quinazolines in 2 studies
| Studies (vadimezan) | Trials (vadimezan) | Recent Studies (post-2010) (vadimezan) | Studies (quinazolines) | Trials (quinazolines) | Recent Studies (post-2010) (quinazolines) |
|---|---|---|---|---|---|
| 272 | 16 | 101 | 19,235 | 2,417 | 8,835 |
| Protein | Taxonomy | vadimezan (IC50) | quinazolines (IC50) |
|---|---|---|---|
| Epidermal growth factor receptor | Homo sapiens (human) | 0.027 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Döme, B; Magyar, M | 1 |
| Lenihan, DJ; Subbiah, IM; Tsimberidou, AM | 1 |
1 review(s) available for vadimezan and quinazolines
| Article | Year |
|---|---|
[Tumor vasculature as a therapeutic target in non-small cell lung cancer].
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Axitinib; Benzenesulfonates; Bevacizumab; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Humans; Imidazoles; Indazoles; Indoles; Lung Neoplasms; Niacinamide; Oligonucleotides; Phenylurea Compounds; Piperidines; Pyridines; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Recombinant Fusion Proteins; Sorafenib; Sulfonamides; Xanthones | 2008 |
1 other study(ies) available for vadimezan and quinazolines
| Article | Year |
|---|---|
Cardiovascular toxicity profiles of vascular-disrupting agents.
Topics: Angiogenesis Inhibitors; Bibenzyls; Cardiovascular System; Clinical Trials as Topic; Humans; Neoplasms; Neovascularization, Pathologic; Organophosphorus Compounds; Quinazolines; Serine; Xanthones | 2011 |